Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RAPT Therapeutics (RAPT) Net Income towards Common Stockholders: 2018-2023

Historic Net Income towards Common Stockholders for Therapeutics (RAPT) over the last 6 years, with Dec 2023 value amounting to -$127.1 million.

  • Therapeutics' Net Income towards Common Stockholders fell 35.96% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 48.10%. This contributed to the annual value of -$127.1 million for FY2023, which is 48.10% down from last year.
  • Latest data reveals that Therapeutics reported Net Income towards Common Stockholders of -$127.1 million as of FY2023, which was down 48.10% from -$85.8 million recorded in FY2022.
  • Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$43.0 million for FY2019, and its period low was -$127.1 million during FY2023.
  • Over the past 3 years, Therapeutics' median Net Income towards Common Stockholders value was -$85.8 million (recorded in 2022), while the average stood at -$94.0 million.
  • Data for Therapeutics' Net Income towards Common Stockholders shows a maximum YoY crashed of 48.10% (in 2023) over the last 5 years.
  • Over the past 5 years, Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$43.0 million in 2019, then declined by 23.01% to -$52.9 million in 2020, then slumped by 30.84% to -$69.2 million in 2021, then fell by 23.97% to -$85.8 million in 2022, then tumbled by 48.10% to -$127.1 million in 2023.